What options are available for refractory pancreatic cancer?
نویسندگان
چکیده
Currently gemcitabine-based regimens and FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) are widely used standard for first-line treatment of patients with advanced pancreatic adenocarcinoma. Refractory patients may receive either FOLFOX (5-fluorouracil and oxaliplatin) or gemcitabine based on the first line regimen. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #248 and #373 of the meeting.
منابع مشابه
مروری بر سبب‌شناسی و مارکرهای زیستی دخیل در تشخیص سرطان پانکراس با تاکید بر نقش دیابت در بروز این بیماری: مقاله مروری
Cancer is the major cause of death in the world and the rate of mortality is higher in developed countries. Therefore, lifestyle could be effective in promoting the cancer. The pancreatic tumors, are 8th cause of mortality due to cancer, which have several types, among them ductal adenocarcinoma is the most common and includes 85% of cases. Since, it is almost impossible to diagnosis the tumor ...
متن کاملNonconventional therapeutic modalities in refractory angina pectoris
Abstract Despite sophisticated conventional medical treatment and the continued development and improvement of coronary revascularization modalities in recent years, a significant number of patients still suffer from refractory angina pectoris and cannot be successfully managed. Advances in therapeutic options have led to an increase in the average of life expectancy even in such ...
متن کاملOptimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?
Since the birth of fluorouracil (5-FU) 50 years ago, we have made only incremental changes in clinical outcomes in pancreatic cancer. Gemcitabine remains to be the only standard of care in advanced pancreatic cancer since mid-1990s [1]. Numerous trials which enrolled thousands of patients failed to improve the outcome significantly beyond gemcitabine. At present time, data set in 2 line setting...
متن کاملMetastatic pancreatic cancer: what can nurses do?
The median survival of patients with metastatic pancreatic cancer is three to six months, making the diagnosis difficult to accept for patients, family, and healthcare providers. Therapeutic options are improving, but the treatment of advanced disease remains palliative. For oncology nurses, understanding the therapeutic and palliative options can provide these patients and their caregivers wit...
متن کاملPhase II trial of oral rubitecan in previously treated pancreatic cancer patients.
BACKGROUND Additional systemic treatments for locally advanced or metastatic pancreatic cancer are needed, as current treatment options produce only modest survival benefits. Rubitecan (Orathecin; Supergen Inc., Dublin, CA, http://www.supergen.com) is an orally active camptothecin derivative with demonstrated responses in patients with pancreatic cancer in early clinical trials. This phase II, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- JOP : Journal of the pancreas
دوره 13 2 شماره
صفحات -
تاریخ انتشار 2012